Cargando…

Anti-lymphangiogenic properties of mTOR inhibitors in head and neck squamous cell carcinoma experimental models

BACKGROUND: Tumor dissemination to cervical lymph nodes via lymphatics represents the first step in the metastasis of head and neck squamous cell carcinoma (HNSCC) and is the most significant predictor of tumor recurrence decreasing survival by 50%. The lymphatic suppressing properties of mTOR inhib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ekshyyan, Oleksandr, Moore-Medlin, Tara N, Raley, Matthew C, Sonavane, Kunal, Rong, Xiaohua, Brodt, Michael A, Abreo, Fleurette, Alexander, Jonathan Steven, Nathan, Cherie-Ann O
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3702388/ https://www.ncbi.nlm.nih.gov/pubmed/23815869 http://dx.doi.org/10.1186/1471-2407-13-320

Ejemplares similares

Topical Curcumin-Based Cream Is Equivalent to Dietary Curcumin in a Skin Cancer Model
por: Sonavane, Kunal, et al.
Publicado: (2012)

Survival outcomes based on systemic agent used concurrently with radiation in human-papillomavirus associated oropharyngeal cancer
por: Mehta, Vikas, et al.
Publicado: (2017)

mTOR inhibitor use in head and neck squamous cell carcinoma: A meta‐analysis on survival, tumor response, and toxicity
por: Patel, Jaimin, et al.
Publicado: (2020)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

Everolimus downregulates STAT3/HIF-1α/VEGF pathway to inhibit angiogenesis and lymphangiogenesis in TP53 mutant head and neck squamous cell carcinoma (HNSCC)
por: Alam, Md Maksudul, et al.
Publicado: (2023)

mTOR, metabolism, and the immune response in HPV-positive head and neck squamous cell cancer
por: Coppock, Joseph D., et al.
Publicado: (2016)

Salivary VEGF: a non-invasive angiogenic and lymphangiogenic proxy in head and neck cancer prognostication
por: Upile, Tahwinder, et al.
Publicado: (2009)

mTOR Signalling in Head and Neck Cancer: Heads Up
por: Tan, Fiona H., et al.
Publicado: (2019)

KSHV Induction of Angiogenic and Lymphangiogenic Phenotypes
por: DiMaio, Terri A., et al.
Publicado: (2012)

mTOR co-targeting strategies for head and neck cancer therapy
por: Wang, Zhiyong, et al.
Publicado: (2017)

PD-L1 promotes head and neck squamous cell carcinoma cell growth through mTOR signaling
por: Zheng, Anyuan, et al.
Publicado: (2019)

Targeting mTOR-CCL20 Signaling May Improve Response to Docetaxel in Head and Neck Squamous Cell Carcinoma
por: Chou, Ming-Huei, et al.
Publicado: (2021)

Identification of Gene Expression Differences between Lymphangiogenic and Non-Lymphangiogenic Non-Small Cell Lung Cancer Cell Lines
por: Regan, Erin, et al.
Publicado: (2016)

Lymphangiogenic factors are associated with the severity of hypersensitivity pneumonitis
por: Yamashita, Masahiro, et al.
Publicado: (2015)

Impact of PI3K/AKT/mTOR pathway activation on the prognosis of patients with head and neck squamous cell carcinomas
por: García-Carracedo, Darío, et al.
Publicado: (2016)

Targeting PI3K/AKT/mTOR Signaling Pathway as a Radiosensitization in Head and Neck Squamous Cell Carcinomas
por: Su, Yu-Chieh, et al.
Publicado: (2022)

Molecular profiling of head and neck squamous cell carcinoma
por: Feldman, Rebecca, et al.
Publicado: (2015)

Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma
por: Erlich, R B, et al.
Publicado: (2012)

Inflammation and Progression of Cholangiocarcinoma: Role of Angiogenic and Lymphangiogenic Mechanisms
por: Roy, Sukanya, et al.
Publicado: (2019)

The connection between lymphangiogenic signalling and prostaglandin biology: A missing link in the metastatic pathway
por: Karnezis, Tara, et al.
Publicado: (2012)

Teenage cervical screening in a high risk American population
por: Zhang, Songlin, et al.
Publicado: (2011)

Dihydroxyacetone suppresses mTOR nutrient signaling and induces mitochondrial stress in liver cells
por: Hernandez, Arlet, et al.
Publicado: (2022)

The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma
por: Ku, Bo Mi, et al.
Publicado: (2016)

Lymphangiogenic Gene Therapy With Minimal Blood Vascular Side Effects
por: Saaristo, Anne, et al.
Publicado: (2002)

Lymphangiogenic therapy prevents cardiac dysfunction by ameliorating inflammation and hypertension
por: Song, LouJin, et al.
Publicado: (2020)

Targeting the Tumor Microenvironment through mTOR Inhibition and Chemotherapy as Induction Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma: The CAPRA Study
por: Evrard, Diane, et al.
Publicado: (2022)

Sildenafil Transiently Delays Early Alveolar Healing of Tooth Extraction Sockets
por: Orchard, Elysse, et al.
Publicado: (2017)

Predictive Value of EGFR-PI3K-AKT-mTOR-Pathway Inhibitor Biomarkers for Head and Neck Squamous Cell Carcinoma: A Systematic Review
por: de Kort, W. W. B., et al.
Publicado: (2021)

Expression patterns of angiogenic and lymphangiogenic factors in ductal breast carcinoma in situ
por: Wülfing, P, et al.
Publicado: (2005)

Plasmin Activates the Lymphangiogenic Growth Factors VEGF-C and VEGF-D
por: McColl, Bradley K., et al.
Publicado: (2003)

Mesenchymal stem cells promote lymphangiogenic properties of lymphatic endothelial cells
por: Robering, Jan W., et al.
Publicado: (2018)

Association Between c-Met and Lymphangiogenic Factors in Patients With Colorectal Cancer
por: Kim, Han Jo, et al.
Publicado: (2018)

Effect of Hypoxia Preconditioned Secretomes on Lymphangiogenic and Angiogenic Sprouting: An in Vitro Analysis
por: Moog, Philipp, et al.
Publicado: (2020)

Anti-lymphangiogenic diterpenes from the bark of Calocedrus macrolepis var. formosana
por: Lee, Tzong-Huei, et al.
Publicado: (2021)

Circulating Human Papillomavirus DNA in Head and Neck Squamous Cell Carcinoma: Possible Applications and Future Directions
por: Adilbay, Dauren, et al.
Publicado: (2022)

Clinicopathological and prognostic significance of mTOR and phosphorylated mTOR expression in patients with esophageal squamous cell carcinoma: a systematic review and meta-analysis
por: Li, Shuangjiang, et al.
Publicado: (2016)

Myelination and mTOR
por: Figlia, Gianluca, et al.
Publicado: (2017)

Prognostic Significance of mTOR and PTEN in Patients with Esophageal Squamous Cell Carcinoma
por: Lu, Jianjun, et al.
Publicado: (2015)

Identification of mTOR inhibitor-resistant genes in cutaneous squamous cell carcinoma
por: Yu, Seong-Lan, et al.
Publicado: (2018)

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
por: Zou, Zhilin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_q5phoe11ckk4d7uqnnslqj2730